Maia Biotechnology

Maia Biotechnology Liabilities

The The Liabilities of Maia Biotechnology (MAIA) as of Nov 10, 2026 is 7.33 M USD. In the previous year, The Liabilities was 6.52 M USD — a change of 12.39% (higher).

Liabilities

7.33 MUSD

YoY

12.39%

Last updated:

In 2025, Maia Biotechnology's total liabilities amounted to 7.33 M USD, a 12.39% difference from the 6.52 M USD total liabilities in the previous year.

The Maia Biotechnology Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
409,737.00 USD
Jan 1, 2020
2.36 M USD
Jan 1, 2021
2.15 M USD
Jan 1, 2022
3.51 M USD
Jan 1, 2023
7.09 M USD
Jan 1, 2024
6.52 M USD
Jan 1, 2025
7.33 M USD
The Maia Biotechnology Liabilities history
YEARLiabilitiesYoY
7.33 MUSD+12.39%
6.52 MUSD-8.02%
7.09 MUSD+101.73%
3.51 MUSD+63.76%
2.15 MUSD-9.18%
2.36 MUSD+476.66%
409,737.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Maia Biotechnology Stock analysis

What does Maia Biotechnology do? MAIA Biotechnology, Inc. generates revenue through the development and commercialization of oncology drug candidates, focusing on targeted immuno-oncology therapies for difficult-to-treat cancers. The company's pipeline includes THIO (6-thio-dG, 6-thio-2’-deoxyguanosine), a telomere-targeting agent in Phase II clinical development for Non-Small Cell Lung Cancer, and Libtayo for advanced non-small-cell lung cancer treatment. MAIA is advancing a second-generation program with five compounds designed to improve specificity towards cancer cells and increase anticancer activity. The firm targets pharmaceutical companies and healthcare providers seeking innovative cancer treatments. The company's primary products are THIO and Libtayo, with THIO being a potentially first-in-class small molecule. MAIA is developing these therapies to improve and extend the lives of cancer patients, focusing on non-small-cell lung cancer and other difficult-to-treat cancers. The firm's second-generation pipeline aims to discover new compounds with enhanced properties compared to existing therapies. MAIA's clinical-stage approach allows it to partner with pharmaceutical entities for development and commercialization. MAIA Biotechnology's revenue model relies on the progression of its clinical-stage therapies through development phases, with potential partnerships and licensing agreements for commercialization. The company's focus on telomere-targeting agents like THIO positions it in the oncology drug development market. MAIA's pipeline includes Phase II studies for THIO in Non-Small Cell Lung Cancer, indicating near-term potential for partnerships or sales. The firm targets healthcare providers and pharmaceutical companies as key segments for its therapies. Maia Biotechnology is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Maia Biotechnology's Liabilities

Maia Biotechnology's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Maia Biotechnology's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Maia Biotechnology's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Maia Biotechnology's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Maia Biotechnology’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Maia Biotechnology stock

The Liabilities of Maia Biotechnology is 7.33 M USD in 2025.

The Liabilities of Maia Biotechnology changed from 6.52 M USD to 7.33 M USD, representing a 12.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Maia Biotechnology since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Maia Biotechnology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Maia Biotechnology

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Maia Biotechnology